KK
IOVA icon

KLP Kapitalforvaltning’s Iovance Biotherapeutics IOVA Stock Holding History

KLP Kapitalforvaltning’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330K Buy
79,300
+10,900
+16% +$41.4K ﹤0.01% 1687
2026
Q1 		$240K Buy
68,400
+6,000
+10% +$19.2K ﹤0.01% 1752
2025
Q4 		$170K Hold
62,400
– – ﹤0.01% 1898
2025
Q3 		$135K Buy
62,400
+21,700
+53% +$51.2K ﹤0.01% 1975
2025
Q2 		$70K Hold
40,700
– – ﹤0.01% 2115
2025
Q1 		$136K Hold
40,700
– – ﹤0.01% 1901
2024
Q4 		$301K Buy
+40,700
New +$377K ﹤0.01% 1648

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

KLP Kapitalforvaltning's IOVA Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Iovance Biotherapeutics (IOVA) stake by 16% in Q2 2026, buying an estimated $41.4K and bringing the position to 79,300 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #1687.

KLP Kapitalforvaltning first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • KLP Kapitalforvaltning held 79,300 shares of Iovance Biotherapeutics worth $330K as of Q2 2026.
  • KLP Kapitalforvaltning bought 10,900 Iovance Biotherapeutics shares in Q2 2026, an estimated $41.4K.
  • Iovance Biotherapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1687 holding.
  • KLP Kapitalforvaltning first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.